This is a prospective, open, single-center study evaluating the efficacy and safety of surufatinib Combined With Temozolomide and S-1 as the first-line treatment of advanced neuroendocrine tumors
Aged 18-75years (inclusive);
Histopathologically confirmed diagnosis of advanced MGMT0/1+ (G1, G2 or G3) neuroendocrine tumor (locally advanced, unresectable or distant metastasis);
Previously untreated with systemic therapy;
Have at least one measurable lesion according to RECIST v1.1;
Neuroendocrine cancer, adenocarcinoid, goblet cell carcinoid,
Functional NETs which need to control symptoms by long-acting somatostatin analogues;
Received a major surgery which requires at least 3 weeks after recovery time, to undergo surgery on treatment of this research within 4 weeks prior to treatment;
Have uncontrolled hypertension, defined as systolic blood pressure >140 mmHg or diastolic blood pressure >90 mm Hg, while under anti-hypertension treatment;